Previous Article | Next Article ![]()
Journal of Virology, October 1999, p. 8813-8816, Vol. 73, No. 10
Genetic Therapy, Inc., a Novartis Company,
Gaithersburg, Maryland 20878
Received 24 March 1999/Accepted 7 July 1999
Retroviral vectors for gene therapy are designed to minimize the
occurrence of replication-competent retrovirus (RCR); nonetheless, it
is possible that a vector-derived RCR could establish an infection in a
patient. Since the efficacy of antiretroviral agents can be impacted by
interactions between virus, host cell, and drug, five commonly used
antiretroviral drugs were evaluated for their abilities to inhibit the
replication of a murine leukemia virus (MLV)-derived RCR in human
cells. The results obtained indicate that the combination of nucleoside
analogs zidovudine and dideoxyinosine with the protease inhibitor
indinavir effectively inhibits MLV-derived RCR replication in three
human cell lines. In addition, MLV-derived RCR was found to be
inherently resistant to the nucleoside analogs lamivudine and
stavudine, suggesting that mutations conferring resistance to
nucleoside analogs in human immunodeficiency virus type 1 have the same
effect even in an alternative viral backbone.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Efficacy of Antiretroviral Agents against Murine
Replication-Competent Retrovirus Infection in Human Cells
*
Corresponding author. Mailing address: Genetic Therapy,
Inc., 938 Clopper Rd., Gaithersburg, MD 20878. Phone: (301) 258-4760. Fax: (301) 258-4757. E-mail: sharon.powell{at}pharma.novartis.com.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»